Dpi formulation containing sulfoalkyl ether cyclodextrin
AssigneeCydex, Inc.
InventorsJAMES PIPKIN, RUPERT ZIMMERER, ANTHONY HICKEY, DIANE THOMPSON, HUGH SMYTH
Life of this patent
Estimating the term…
Loading patent…
AssigneeCydex, Inc.
InventorsJAMES PIPKIN, RUPERT ZIMMERER, ANTHONY HICKEY, DIANE THOMPSON, HUGH SMYTH
Estimating the term…
An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
An inhalable dispersible dry powder formulation comprising:
An inhalable therapeutic dry powder adapted for administration to a subject with a DPI device, the powder comprising a physical mixture comprising:
An inhalable therapeutic dry powder adapted for administration to a subject with a DPI device, the powder comprising a physical mixture comprising:
29-44. (canceled)
A dry powdered particulate carrier composition comprising an SAE-CD of the Formula 1 or Formula 2 and optionally one or more excipients, wherein the carrier composition possesses the following properties:
A method of preparing a dry powder carrier composition suitable for use in a DPI device for the delivery of an active agent to a subject, the method comprising the steps of:
47-51. (canceled)
Dependencies are inferred from the claim text.